JAMA Neurol: application of flortaucipir PET in AD neuropathology change detection

Currently, positron emission tomography (PET) is the most effective way to confirm potential neuropathological changes in Alzheimer's disease (A D)Recently, the researchers compared the difference s(18F) flortaucipir PET results with the AD tau pathology in the autopsyA16 study was conducted in the United States and Australia, involving patients with terminal lyme soldering diseases older than 50 years and life expectancy of less than 6 months, and all participants received the image of the pet pet of the 18F.18FA supplementary autopsy is performed upon the patient's deathThe main endpoint of the study was a comparison of the results of the flortaucipir PET with the immune heta-tau pathologya total of 156 patients participated in the A16 study, of which 73 died during the study, of which 67 were subjected to an effective autopsyThe average age of the completed autopsy patients was 82.5 years, 49 (77%) had dementia, 1 (2%) had mild cognitive impairment and 14 (22%) had cognitive normalityThe sensitivity of the flortaucipir PET scan predicted tau was 92.3% to 100.0% and the specificity was 52.0% to 92.0%Flortaucipir PET scans predicted high levels of AD neuropathy, sensitivity from 94.7% to 100.0% and specificity from 50.0% to 92.3%studies have shown that the petasopic PET imaging of the type of aD tau can be used to identify the density and distribution of AD tau pathology, as well as high levels of AD neuropathological changes, supporting neuropathological diagnosis of AD